Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01654120 · ClinicalTrials.gov registry record · Phase 4
Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics
A Phase 4 study of Diabetes Mellitus Type II, sponsored by Mountain Diabetes and Endocrine Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT01654120: Completed Phase 4 study of Diabetes Mellitus Type II, sponsored by Mountain Diabetes and Endocrine Center.
NCT01654120 is a Phase 4 study of Diabetes Mellitus Type II that has completed, run by Mountain Diabetes and Endocrine Center. The registered enrollment target is 37 participants, below the 235-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01654120, a Phase 4 study of Diabetes Mellitus Type II, has completed, sponsored by Mountain Diabetes and Endocrine Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effect of adding liraglutide to high dose insulin therapy compared to high dose insulin therapy alone in patients with insulin-treated Type 2 diabetes with insulin requirements of \> 100 units of insulin per day.
Primary Outcome
Glycemic control as measured by HbA1c
Conditions Studied
Interventions
- DRUG Liraglutide
- DRUG Insulin
Study Locations (1)
North Carolina
- Mountain Diabetes and Endocrine Center - Asheville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
What the finished NCT01654120 record still lists
NCT01654120 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 235-participant average among 7 other Diabetes Mellitus Type II trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Diabetes Mellitus Type II appearing as the primary indexed condition, and to 2 interventions - of which Liraglutide is the first listed.
NCT01654120 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01654120 about?
NCT01654120 is a clinical study titled "Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics". The purpose of this study is to determine the effect of adding liraglutide to high dose insulin therapy compared to high dose insulin therapy alone in patients with insulin-treated Type 2 diabetes with insulin requirements of \> 100 units of insulin per day.
What is the current status of trial NCT01654120?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2011-12. Estimated completion is 2013-11.
What conditions does trial NCT01654120 study?
This clinical trial studies the following conditions: Diabetes Mellitus Type II.
What interventions are being tested in trial NCT01654120?
The interventions under investigation include: Liraglutide (DRUG), Insulin (DRUG).
Who is sponsoring clinical trial NCT01654120?
This trial is sponsored by Mountain Diabetes and Endocrine Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01654120 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus Type II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery
RECRUITING · NA
-
Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana
ACTIVE NOT RECRUITING
-
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
-
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
COMPLETED · Phase 2
-
GOLO Open-Label Pilot 1
COMPLETED · NA
-
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia